The failed Phase III program removes a potential future revenue stream in RCC, a market with limited treatment options. For a $106.9B diversified pharma, this is a modest pipeline blow rather than a transformative event. Monitor the BALANCE trial in IBS-D/IBS-M for any remaining value in the camlipixant program, and watch for potential write-downs in the next quarterly filing. The stock may see a small negative reaction as the market prices out RCC peak sales expectations.
Drug in focus
GSK drug pipeline →camlipixant
▼ Bearish Named in this 6-K- Impact
- Phase
- Phase 3 (lead indication discontinued); Phase IIb ongoing in IBS-D/IBS-M
- Time to market
- Unknown in the surviving IBS indication (Phase IIb — still years from any possible filing); effectively zero path to market in its lead indication, refractory chronic cough, where development was discontinued in July 2026.
- Next catalyst
- None dated
What to watchThe defining binary has already passed and it was a miss: GSK booked a ~£1.9B impairment tied mostly to camlipixant that cut Q2 2026 operating profit by ~75% (to £481M), yet the stock is only a few percent off its 52-week high, confirming the drug is immaterial to a company this size. For GSK holders, watch the remaining Phase IIb IBS-D/IBS-M program for any signs of continued investment (or an eventual full exit from P2X3), and track competitors still chasing chronic cough (e.g., Trevi's Haduvio, Addex) as the class's commercial benchmark.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 17 $51.76entry
- T+1 · 4mo ago −3.32%α −3.16% · $50.04
- T+5 · 4mo ago −1.97%α −1.28% · $50.74
- T+20 · 3mo ago −4.33%α −8.77% · $49.52
- T+60 · 5w ago −9.35%α −14.03% · $46.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK announced that its Phase III CALM-1 trial for camlipixant in refractory chronic cough met its primary endpoint (50mg BID at week 12), but the confirmatory CALM-2 trial failed to reach statistical significance on the same endpoint at week 24. The 25mg dose missed in both studies, and key secondary endpoints did not meet thresholds. Based on limited efficacy, GSK is discontinuing further development of camlipixant in RCC, though a Phase IIb trial in IBS-D/IBS-M continues. This is a clear pipeline setback for a mid-stage asset, though the financial impact is limited given GSK's scale ($106.9B market cap). The cross-filing context includes the 20-F annual report from March 2026, which provides baseline financial context but does not alter this filing's standalone interpretation. The cross-filing actuarial verdicts flag this as an amplifier combo (6k-activist-context + 6k-annual-context), but no activist context is present in the provided filings, so no override is applied.
Key Facts
- CALM-1 met primary endpoint (camlipixant 50mg BID showed statistically significant reduction in 24-hour cough frequency vs placebo at week 12)
- CALM-2 did not reach statistical significance on the same primary endpoint with 50mg BID at week 24
- Camlipixant 25mg BID did not reach statistical significance in either study
- Key secondary endpoints, including Chronic Cough Diary measure, did not meet target thresholds in either study
- GSK has decided not to progress further development of camlipixant in RCC
- Phase IIb BALANCE trial in IBS-D/IBS-M will continue
Financial Impact
Pipeline setback with no disclosed financial figures; R&D spend on camlipixant not quantified in filing
Risk Factors
- Complete discontinuation of camlipixant in RCC eliminates a potential growth driver in a high-unmet-need area
- BALANCE trial in IBS-D/IBS-M may also fail, rendering the entire camlipixant program worthless
- No disclosed financial impact or R&D impairment charge, leaving uncertainty about the scale of sunk costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (GSK), Batch item 1 | 0001654954-26-006705 |
| Document: 0001654954-26-006705-index-headers.html | 0001654954-26-006705 |
| Document: 0001654954-26-006705-index.html | 0001654954-26-006705 |
| Document: 0001654954-26-006705.txt | 0001654954-26-006705 |
| 6-K Filing (GSK), Batch item 5 | 0001654954-26-006705 |
| Document: 0001654954-26-006705-index-headers.html | 0001654954-26-006705 |
| Document: 0001654954-26-006705-index.html | 0001654954-26-006705 |
| Document: 0001654954-26-006705.txt | 0001654954-26-006705 |
Track record
64 reports on GSK
8 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +4.85% at T+5 after the Jul 22, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers